

REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study

NCT06108427

Status	RECRUITING
Phase	Not Applicable
Sponsor	Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Enrollment	58 participants

Key Eligibility Criteria

Inclusion (4)

- Over 18 years of age
- Diagnosis of PA, in accordance with clinical guidelines and local practice
- Suppressed plasma renin prior to treatment initiation (plasma renin concentration $\gt 15$ mIU/L or $\gt 10$ ng/L, or plasma renin activity $\gt 1$ ng/mL/h)
- Planned long-term treatment with mineralocorticoid receptor antagonist

Exclusion (8)

- Prior use of mineralocorticoid receptor antagonist or any potassium-sparing diuretics in the past 3 months
- Known intolerance or contraindication to mineralocorticoid receptor antagonist treatment
- eGFR $\lt 30$ ml/min/1.73m² (past 3 months)
- Baseline serum potassium above $\gt 4.8$ mmol/L (past 3 months)
- Deemed medically unsafe to stop medications for the initiation of MRA as monotherapy
- ... and 3 more (see full listing online)

Locations (1 total)

Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada